TNC and glioblastoma: Shi et al. developed these dual-modalities by conjugating GBM-cell-specific peptides (P1NS) and antibodies (anti-GBM, i.e., tenascin-C (TN-C)) to the liposomes, co-loaded with SPIONs and DOX [67].